• Biomarker Combo Could Guide Treatment of Recurring Ovarian Cancer

    Sep 17 | Diagnostics World | Ovarian cancer relapse is a remarkably diverse and dynamic immunological event that when mapped in conjunction with the genomic characteristic of tumors can provide actionable insights about how to enhance the effectiveness of chemotherapy in extending remission and prolonging survival. That’s the promising possibility suggested by researchers in the field who have newly defined four immunologic subtypes of recurrent ovarian cancers. More

  • AI-Stethoscope Increases Cardiac Condition Diagnoses in Routine Care

    Sep 16 | Diagnostics World | Results from one of the largest randomized evaluations of AI in routine care showed that an AI-enabled digital stethoscope significantly increased the number of major cardiac conditions detected compared to the standard of care. The study was led by Imperial College London and Imperial College Healthcare NHS Trust and the results were presented last week at the European Society of Cardiology Congress in Madrid. More

  • Qure.ai Scans Routine Chest X-Rays for Early Cancer Diagnoses

    Sep 11 | Diagnostics World | A clinical case study from Qure.ai and Hacettepe University, Turkey, delivered at the IASLC World Conference on Lung Cancer 2025 in Barcelona, shows that Artificial Intelligence (AI) can detect potentially malignant pulmonary nodules on routine chest X-rays, even when the imaging was ordered for unrelated, non-respiratory conditions. More

  • Decoding Immune Cell Dialogue to Predict Immunotherapy Responses

    Sep 09 | Diagnostics World | There is a lack of reliable predictive methods that can determine how a patient will respond to certain immunotherapies and understanding how immune cells communicate with each other may be the key to understanding the differences. A team of researchers have created a new technology called Interact-omics that can “listen in” on this immune cell dialogue. More

  • The Great Debate Over AI’s Role in the Microbiology Lab

    Sep 04 | Diagnostics World | In a lively matchup between clinical microbiology experts at the recent Next-Generation Dx Summit, onlookers already predisposed to believing artificial intelligence (AI) would not be replacing conventional microbiology and infectious disease testing in the next 10 years were further swayed toward dismissing the possibility. It perhaps helped that the deciding vote on the debate came immediately after the person arguing mightily about the inevitability of an AI takeover himself switched from the affirmative to the negative position. More

  • Point-of-Care Testing Finding Its Way in Clinical Care

    Sep 03 | Diagnostics World | An assortment of “hot-button issues” in point-of-care testing (POCT) remain to be sorted out amid rising patient demand for access to rapid and reliable tests results, mounting financial pressures on healthcare systems, and ongoing concerns about the setting and timing of testing to reap the most clinical benefits. Having actionable results, improving connections to care, and balancing patient anonymity with public health reporting in sexually transmitted infection (STI) testing are among the current topics of dialogue, as highlighted during the Next-Generation Dx Summit held last month. More

  • Pacific Biosciences Develops Family-Based Genomics Benchmark to Sharpen Diagnostic Accuracy

    Sep 02 | Diagnostics World | When it comes to disease diagnostics, every missed genetic variant represents a delay in diagnosis—and often in treatment. Researchers at Pacific Biosciences (PacBio) developed a new genomic benchmark that could help close those diagnostic gaps, offering more accurate detection of genetic variants. More

  • Follow the Money: Programmable mRNA Therapeutics, Neurodegenerative Disease Treatment, More

    Aug 27 | Diagnostics World | Strand Therapeutics will advance their pipeline of STX-001, a programmable mRNA therapy that expresses the cytokine interleukin-12 (IL-12) directly from the tumor microenvironment; Jocasta Therapeutics plan to further develop a - Klotho, a protein therapeutic targeting cognitive decline in neurodegenerative diseases; and more. More

  • Roche Receives FDA Clearance, Dana-Farber Develops Multiple Myeloma Blood Test, More

    Aug 26 | Diagnostics World | Roche announced the US Food and Drug Administration (FDA) 510(k) clearance for the cobas Respiratory 4-flex; Dana-Farber Cancer Institute researchers have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma; and more. More

  • Boston Children’s Hospital, Broad Clinical Labs, Dana-Farber Cancer Institute Launch Research Initiative

    Aug 21 | Diagnostics World | Earlier this month, Boston Children’s Hospital, Broad Clinical Labs, and Dana-Farber Cancer Institute announced the formation of a collaborative clinical research and testing initiative, Boston Research in Innovative Genomics for Hematologic and Tumor Sequencing (BrightSeq). More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more